Analysing heart disease with Applied Biosystems' Expression Array System
News Sep 20, 2005
Researchers at the Leiden/Amsterdam Center for Drug Research (LACDR) have announced that they are using the Applied Biosystems Expression Array System to identify genes that may predispose towards atherosclerosis, and validating them using Applied Biosystems' TaqMan® Gene Expression Assays.
"We mainly focus on gene expression in the liver, where we are particularly interested in lipid metabolism and homeostasis, and on monocytes and T cells in the immune system,” explained Dr Johan Kuiper, associate professor at the LACDR.
“We are comparing gene expression in diseased and treated diseased samples with normal samples."
"The Applied Biosystems 1700 Analyzer, which is part of the Expression Array System, has been excellent, it is very sensitive and we are really happy with the data.”
“We have run a number of experiments and, in particular, there is very good correlation between the gene expression patterns we find using the 1700 Analyzer and with the TaqMan assays.”
“We chose the 1700 Analyzer for several reasons, including the internal standards, which allow us to get an absolute value for a gene's expression level, and the ease of analysing the arrays - we do not have to draw grids around the spots during the analysis.”
“We hope to eventually identify specific genes and pathways or genetic mutations that might be involved in atherosclerosis development."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.